“We are proud the ELF Test was recognized as a top-performing biomarker, with potential to reshape the way NASH clinical trials are performed. We know that liver biopsies remain a major barrier for clinical trial enrollment. The study results are encouraging and demonstrate that non-invasive biomarkers provide the potential to improve the way in which we identify NASH, and evaluate treatment efficacy."
President, Laboratory Diagnostics
“The results of this Stage 1 study represent a significant milestone for the NIMBLE initiative getting us closer to a better, less invasive way to conduct clinical research by reducing the need for biopsy.”
Director of Metabolic Disorders, FNIH
“We are at the first step to revolutionizing clinical trials in NASH, and look forward to our continued collaboration with NIMBLE in the pursuit of regulatory qualification.“
President, Laboratory Diagnostics, Siemens Healthineers